Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 11 Jan 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
No new digest content identified.

 

BMGF – Gates Foundation [to 11 Jan 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 11 Jan 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 11 Jan 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
01.08.2020  |
CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics
CARB-X is awarding TAXIS Pharmaceuticals of Monmouth Junction, New Jersey, USA, up to US$3.2 million in non-dilutive funding to develop efflux pump inhibitors (EPI), a new drug class designed to destroy a major mechanism of multi-drug-resistant Pseudomonas aeruginosa bacteria. TAXIS is eligible for additional funding of up to $11.4 million if the project achieves certain milestones. TAXIS’ EPIs are designed to disable the bacteria’s efflux pumps, which act like bilge pumps to flush out antibiotics from the bacterial cell in order to safeguard the superbug from the effects of antibiotics.

01.07.2020  |
CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria
CARB-X is awarding Centauri Therapeutics of Sandwich, UK, up to $1.4 million in non-dilutive funding to develop a novel dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens, including drug-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 Jan 2020]
http://cepi.net/
Latest news
No new digest content identified.

 

Clinton Health Access Initiative, Inc. (CHAI) [to 11 Jan 2020]
https://clintonhealthaccess.org/
News & Press Releases
No new digest content identified.

 

EDCTP [to 11 Jan 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

 

Emory Vaccine Center [to 11 Jan 2020]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 11 Jan 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
No new digest content identified.

 

European Vaccine Initiative [to 11 Jan 2020]
http://www.euvaccine.eu/news-events
No new digest content identified.

 

FDA [to 11 Jan 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
No new digest content identified.

 

Fondation Merieux [to 11 Jan 2020]
http://www.fondation-merieux.org/
News, Events
20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)

 

Gavi [to 11 Jan 2020]
https://www.gavi.org/
No new digest content identified.
GHIT Fund [to 11 Jan 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 11 Jan 2020]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

 

Hilleman Laboratories [to 11 Jan 2020]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 11 Jan 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

 

IAVI [to 11 Jan 2020]
https://www.iavi.org/newsroom
No new digest content identified.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
Geneva, 7 January 2020
Hanan Sboul takes over the position of IGBA Chair
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers, is taking over the position of IGBA Chair for 2020 from Jim Keon, President of the Canadian Generic Pharmaceutical Association and Biosimilars Canada.
Key milestones were achieved for the IGBA during 2019, namely the signature of a memorandum of understanding with the World Health Organization (WHO) to promote accessi and the adoption by the International Council for Harmonization (ICH) of a new topic proposal on bioequivalenceii…

 

 

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

 

IFRC [to 11 Jan 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Asia Pacific
Red Cross releases funds in anticipation of extreme winter in Mongolia
Forecasts of an extreme winter in Mongolia have triggered the release of funding to reduce its impact on vulnerable herders. This is the first time this early action funding mechanism developed by the International Federation of Red Cross and Red Crescent Societies (IFRC) has been used anywhere.
9 January 2020

 

IVAC [to 11 Jan 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
No new digest content identified.

 

IVI [to 11 Jan 2020]
http://www.ivi.int/
Selected IVI News & Announcements
IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand
January 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) received a $1.4 million grant from the Bill & Melinda Gates Foundation to ensure critical standards and reagents are available to low-cost oral cholera vaccine (OCV) manufacturers in the global health market. International standardization in the manufacturing and release of OCV will ultimately ensure sufficient supply of low-cost prequalified vaccines in the 39 Gavi countries, where demand currently exceeds the supply.

There are currently no International Standards or reference reagents available to vaccine manufacturers to test the cholera vaccine antigens containing bulk drug substances or products. This lack of standardization led IVI to organize a meeting in May 2018 on “International Standards for Oral Whole Cell Killed Cholera Vaccines,” funded by the Gates Foundation. Representatives from leading research institutions and national regulatory agencies attended the meeting, as well as field experts in inactivated killed OCV from the World Health Organization (WHO) and the National Institute for Biological Standards and Control (NIBSC), to outline consensus on the specification of reagents for LPS inhibition ELISA to be established as WHO International Standards.

“Making available reference reagents will ensure uniform efficacy and allow multiple manufacturers to scale up production of low-cost cholera vaccine, which currently can’t fulfill global demand,” says Dr. Ravi Ganapathy, Head of Vaccine Process Development at IVI…

 

JEE Alliance [to 11 Jan 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 11 Jan 2020]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

 

National Vaccine Program Office – U.S. HHS [to 11 Jan 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 11 Jan 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
No new digest content identified.

 

PATH [to 11 Jan 2020]
https://www.path.org/media-center/
Selected Announcements
No new digest content identified.

 

Sabin Vaccine Institute [to 11 Jan 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 11 Jan 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
9 January 2020
UNAIDS Executive Director urges Uganda to do more domestically

 

UNICEF [to 11 Jan 2020]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Statement
UNICEF calls on all stakeholders to put children first and ensure their safeguarding in these times of crisis in Lebanon
Statement by Yukie Mokuo, UNICEF Representative in Lebanon
10/01/2020

Press release
UNICEF Goodwill Ambassador Liam Neeson joins the call to ramp up support to Venezuelan migrant children during visit to Brazil-Venezuela border
10/01/2020

Press release
Fighting in and around Tripoli shuts 210 schools, depriving over 115,000 children of their education
06/01/2020

 

Vaccination Acceptance Research Network (VARN) [to 11 Jan 2020]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 11 Jan 2020]
http://www.vaccineconfidence.org/
No new digest content identified.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 11 Jan 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 11 Jan 2020]
https://wellcome.ac.uk/news
News | 9 January 2020
Katie Anastasi-Frankovics is Wellcome’s new Director of Innovations
We are making two new appointments to Wellcome’s Executive Leadership Team (ELT) – Katie Anastasi-Frankovics is becoming Director of Innovations and Karen Chadwick is now Finance Director.

 

The Wistar Institute [to 11 Jan 2020]
https://www.wistar.org/news/press-releases
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 11 Jan 2020]
https://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 11 Jan 2020]
https://alliancerm.org/press-releases/
January 10, 2020
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
WASHINGTON, D.C. – January 10, 2020 – The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today announced the release of a report, “A Transformative Therapy Value Model for Rare Blood Diseases.” The report uses a refined value model to assess the impact of durable and potentially curative cell and gene therapies on health system costs.

Produced by the Marwood Group with support from ARM, the report calculates the potential cost savings that a durable cell or gene therapy could provide when treating patients with multiple myeloma, hemophilia A, or sickle cell disease. Under the current standard of care, these three disease states are projected to cost the United States healthcare system $163B per year by 2029.

Key findings from the report include:
:: The total potential savings of cell and gene therapies range from 18% to 30% in annual total disease costs and productivity. This represents an aggregate cost savings of more than $33B over ten years.
:: The modeled cost savings were highest in multiple myeloma patients ($27B in cumulative savings per year by 2029) due to the high cost of the current standard of care and to greater productivity losses experienced by the adult children caregivers of older patients.
:: Innovative financing models, such as subscription models, payment-over-time, and value-based payments, are needed to help payers offset the potentially high upfront costs of these therapies and realize longer term cost-savings…

 

BIO [to 11 Jan 2020]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 11 Jan 2020]
http://www.dcvmn.org/
News
DCVMN International welcomes newly formed Executive Committee 2020-23
Geneva, 02 January 2020 – At its 20th Annual General Meeting held in Rio, on October 22nd 2019, the Developing Countries Vaccine Manufacturers Network international members elected, among its nominated membership, the new Executive Committee members, who volunteer their time and expertise to ensure the success of the Network.
We are pleased to announce the new Executive Committee, composed of seven voting members including Sai Prasad, from Bharat Biotech, India; Patrick Tippoo, from Biovac, South Africa; Tiago Rocca, from Butantan, Brazil; Lingjiang Yang, from CNBG, China; Fernando Lobos, from Sinergium, Argentina; Weidan (Wendy) Huang, from Innovax, China and Adriansjah Azhari, from Biofarma, Indonesia…

 

IFPMA [to 11 Jan 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

PhRMA [to 11 Jan 2020]
http://www.phrma.org/
Selected Press Releases, Statements
Press Release
New Analysis Finds Nearly 50% of Brand Medicine Spending Goes to the Supply Chain and Others
The Share of Total Spending for Brand Medicines Retained by the Supply Chain and Others Increased from 33% in 2013 to 46% in 2018
January 9, 2020
Washington, D.C. (January 9, 2020) — Nearly half of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018, according to a new analysis from the Berkeley Research Group (BRG). Innovative biopharmaceutical companies that research, develop and manufacture medicines retained just 54% of total point-of-sale spending on brand medicines. The share of spending received by other stakeholders increased from 33% in 2013 to 46% in 2018.
“This data reaffirms that we need to look at the entire supply chain in order to solve patient affordability challenges,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “We need to fix the misaligned incentives in the supply chain, including the broken rebate system, to ensure patients benefit at the pharmacy counter from the significant discounts and rebates.”…